Place of Flixovate® in the Treatment Pathway and Its Conditions of Use in Infants Aged From 3 to 12 Months Between 2010 and 2012 by French GPs and Private Paediatricians (flixovate HAS)
Status
Conditions
Details and patient eligibility
About
this study has been request by french health authorities to evaluate the use of flixovate in infants and its place in the treatment pathway.
this study has 2 main pbjectives: 1/ Evaluation of changes in the prescription share of Flixovate® compared to other topical corticosteroids (low, medium and high potency) in the population of infants aged from 3 to 12 months, from 1st January 2010 to 31st December 2012. 2/Description of the conditions of use of Flixovate® in infants aged less than 12 months (infant profile, dosage form, dosage, treatment duration, prior, concomitant and subsequent treatments etc.).
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Analysis of changes in share of prescriptions:
- Infants who received at least one prescription of topical steroids between 1st January 2010 and 31st December 2012.
- Infants aged 3 to 12 months on the day of prescription of topical steroids.
Description of the conditions of use and patient profiles:
- Infants who received at least one prescription of topical steroids between 1st January 2010 and 31st December 2012.
- Infants aged 3 to 12 months on the day of prescription of topical steroids.
Exclusion criteria
- none
Trial contacts and locations
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal